Dana-Farber Cancer Institute: Bronchiolitis Obliterans Syndrome trials
The registry lists 10 Bronchiolitis Obliterans Syndrome studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)RecruitingNCT05922761Phase 2
- A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHDCompletedNCT02340676Phase 2Results posted
- An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseTerminatedNCT02123966Phase 2Results posted
- Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseActive, not recruitingNCT01366092Phase 2Results posted
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseTerminatedNCT01226420Phase 2Results posted
- Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host DiseaseCompletedNCT00815919Phase 2Results posted
- Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host DiseaseCompletedNCT00529035Phase 1Results posted
- Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART TrialActive, not recruitingNCT05236062Not applicable
- Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseActive, not recruitingNCT01937468Phase 1
- Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host DiseaseCompletedNCT01221766